share_log

榮昌生物：海外監管公告 - 2024年度向特定對象發行A股股票發行方案的論證分析報告

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 12:25
Summary by Futu AI
荣昌生物宣布將於2024年度向特定對象發行A股股票，以滿足公司業務發展的資金需求，增強資本實力和盈利能力。該公司是上海證券交易所科創板上市公司，此次發行旨在加快公司研發管線項目的臨床、臨床前研究，並推動相關產品在國內外的上市進程。荣昌生物擁有多款候選生物藥產品，其中包括全球首創的B淋巴細胞刺激因子雙靶點創新融合蛋白產品。公司計劃通過此次募集資金投資項目，進一步提升在肿瘤、自身免疫性疾病及眼科領域創新生物藥的研發能力。本次發行股票的數量、價格及具體時間將在獲得中國證監會同意註冊後確定。荣昌生物已就此次發行對即期回報可能產生的摊薄效應進行了分析，並提出了具體的填補回報措施。公司相關主體對填補回報措施能夠得到切實履行作出了承諾。
荣昌生物宣布將於2024年度向特定對象發行A股股票，以滿足公司業務發展的資金需求，增強資本實力和盈利能力。該公司是上海證券交易所科創板上市公司，此次發行旨在加快公司研發管線項目的臨床、臨床前研究，並推動相關產品在國內外的上市進程。荣昌生物擁有多款候選生物藥產品，其中包括全球首創的B淋巴細胞刺激因子雙靶點創新融合蛋白產品。公司計劃通過此次募集資金投資項目，進一步提升在肿瘤、自身免疫性疾病及眼科領域創新生物藥的研發能力。本次發行股票的數量、價格及具體時間將在獲得中國證監會同意註冊後確定。荣昌生物已就此次發行對即期回報可能產生的摊薄效應進行了分析，並提出了具體的填補回報措施。公司相關主體對填補回報措施能夠得到切實履行作出了承諾。
Rong Cheong Bio announced that it will issue A shares to specific audiences in 2024 to meet the capital needs of the company's business development, enhance capital strength and profitability. The company, a listed company on the Shanghai Stock Exchange, is designed to accelerate the clinical and pre-clinical research of the company's R&D pipeline projects and promote the listing process of related products domestically and abroad. Rong Cheong Biologics has several candidate biopharmaceutical products, including the world's first B lymphocyte stimulant factor dual-target innovative fusion protein product. The Company plans to further enhance the R&D capabilities of innovative biopharmaceuticals in the fields of oncology, autoimmune diseases and ophthalmology through this fundraising investment project. The...Show More
Rong Cheong Bio announced that it will issue A shares to specific audiences in 2024 to meet the capital needs of the company's business development, enhance capital strength and profitability. The company, a listed company on the Shanghai Stock Exchange, is designed to accelerate the clinical and pre-clinical research of the company's R&D pipeline projects and promote the listing process of related products domestically and abroad. Rong Cheong Biologics has several candidate biopharmaceutical products, including the world's first B lymphocyte stimulant factor dual-target innovative fusion protein product. The Company plans to further enhance the R&D capabilities of innovative biopharmaceuticals in the fields of oncology, autoimmune diseases and ophthalmology through this fundraising investment project. The number, price and specific timing of the shares to be issued will be determined upon receipt of approval from the China Securities and Exchange Commission for registration. For this release, Rong Cheong Bio has analyzed the possible dilution effects of immediate returns and proposed specific measures for replenishing returns. The relevant entities of the company have made a commitment that the filling return measures can be implemented in practice.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.